RBP1 and liver cancer: In the present study, we revealed that CRBP-1 inhibited the stemness properties of HCC via upregulating WIF1, then suppressed Wnt/β-catenin signaling pathway, which provided a novel therapeutic target for clinical management of liver cancer.